Any buyout should be more then a couple of bucks. In September they had a 1 yr target price of $6.00 Since then the Bio-t-gel has been approved. Libigel may be bigger then expected with the CV benefit. If anyone has actually compared BPAX cancer program to that of other companies you will realize the cancer program itself is worth $3/share. A serious offer should be in the $8- $9 range.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.